Staff editor
Satish Chandran, President and Chief Executive Officer at Prodigy Biotech, Inc., details the company's program aimed at treating alcoholic liver disease, spotlighting Enterococcus faecalis as the primary antagonist.
MicrobiomePost carried out a research analysis in collaboration with Analytics Arts to find out more about the motivations and frequency of probiotic consumption and the level of consumer information.
These findings underscore MaaT013's potential as a third-line treatment option, where traditional treatments often fall short.
Researchers at the San Gallicano Dermatological Institute in Rome, Italy, conducted an open-label exploratory trial to assess the therapeutic potential of EUTOPLAC, a topical probiotic containing Lactobacillus crispatus P 17631…
Aran Singanayagam, research group leader at Imperial College London (UK), examined how disturbances in the airway microbiome are instrumental in the development of chronic lung diseases.
Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.
An exclusive interview with Daniel Brownell, Senior Director of Research & Development at AOBiome Therapeutics, whose core technology is ammonia oxidizing bacteria, formulated as a topical suspension of bacteria applied…
Antonio Gomes, Principal Scientist at Xbiome, talks about employing deep learning techniques to refine the prediction of natural product structures directly from gene sets.
The two companies will work on identifying, analyzing, and understanding respiratory tract microbiome systems.
Elran Haber, CEO at Biomica Ltd, discussed the emerging role of microbiome-based treatments in cancer care.
